Stay updated on SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Sign up to get notified when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page adds a recruitment-closed notice and new user-help sections (How to Read a Study Record, Common Questions, How to Join a Study); the Intervention/Treatment header is updated and the revision version is changed to v3.6.0.
    Difference
    0.2%
    Check dated 2026-06-15T05:52:41.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    Footer text now shows Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a version tag update for the page rather than a change to study content.
    Difference
    0.0%
    Check dated 2026-06-08T03:51:52.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4, replacing v3.5.3, representing a minor version update.
    Difference
    0.0%
    Check dated 2026-05-17T09:29:27.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    ClinicalTrials.gov updated the study record revision/date and refined the treatment regimen details (e.g., calaspargase pegol administration description) and monitoring language for trial procedures. It also updated key eligibility/evaluability and primary/expansion outcome descriptions, including the DLT evaluability thresholds for dose-finding and how MRD-negative remission is described for patients under 6 months.
    Difference
    0.9%
    Check dated 2026-04-25T05:27:47.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    - Page revision updated to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-18T03:50:21.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    Added MRD-negative remission rate endpoints for infants and older infants, and expanded exploratory objectives to include PK analyses of calaspargase pegol within the revumenib-plus-chemotherapy regimen. Updated regimen descriptions and cycle structure, and removed certain MRD and PK items from the previous version.
    Difference
    0.8%
    Check dated 2026-04-03T18:37:14.000Z thumbnail image

Stay in the know with updates to SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SNDX-5613 Combo with Chemo in Relapsed Leukemia Clinical Trial page.